Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 18/20 | 0.63 |
| ▸ | CCND1 | P24385 | 10/20 | 0.62 |
| ▸ | CCND3 | P30281 | 9/20 | 0.62 |
| ▸ | CDK4 | P11802 | 8/20 | 0.62 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 6/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.58 |
| ▸ | CDK2 | P24941 | 4/20 | 0.58 |
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727284 | 0.83 | CCND1 (0.54) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL30579744 | 0.83 | CDK6 (0.58) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL20744519 | 0.83 | CDK6 (0.58) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL30541009 | 0.81 | CDK6 (0.68) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL29379886 | 0.78 | CDK6 (0.82) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL28595830 | 0.78 | CDK6 (0.82) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL24664305 | 0.78 | CDK6 (0.66) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL29414458 | 0.78 | CDK6 (1.00) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL28591508 | 0.78 | CDK6 (1.00) | CDK6CCND1CCND3CDK4DYRK2 | |
| SCHEMBL29527689 | 0.78 | CDK6 (0.66) | CDK6CCND1CCND3CDK4DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | CDK6 3/4885CCND1 45/4885CCND3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.